Ocupress®
Carteolol 1% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in chronic open-angle glaucoma or intraocular hypertension
1 drop of 1% in the affected eye(s) BID
Twice-daily dosing gives a median IOP reduction of 22% to 25%.
Elevated IOP inadequately controlled on the twice-daily regimen alone
1 drop of 1% BID plus pilocarpine or another miotic, and/or epinephrine or dipivefrin, and/or a systemic carbonic anhydrase inhibitor such as acetazolamide
Combined with pilocarpine, mean IOP falls 6 to 10 mmHg, a 24% to 40% reduction.
Contraindications
- Bronchial asthma or a history of bronchial asthma.
- Severe chronic obstructive pulmonary disease.
- Sinus bradycardia.
- Second and third degree atrioventricular block.
- Overt cardiac failure.
- Cardiogenic shock.
- Hypersensitivity to any component.
1% solution, 5 mL, 10 mL, 15 mL
Nonselective beta-adrenoceptor blocker with intrinsic sympathomimetic activity and without significant membrane-stabilizing activity; reduces normal and elevated IOP whether or not glaucoma is present. The label states the exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated, and reports no significant effect on corneal sensitivity, tear secretion, or pupil size in the controlled trials.
Warnings & Precautions
- Severe respiratory and cardiac reactions: Carteolol has not been detected in plasma following ocular instillation, but it may be absorbed systemically, and the same adverse reactions found with systemic beta-adrenergic blocking agents may occur with topical administration. Severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported with topical beta-adrenergic blocking agents.
- Cardiac failure: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and beta-blockade may precipitate more severe failure; in patients without a history of cardiac failure, continued myocardial depression over a period of time can, in some cases, lead to failure. Discontinue at the first sign or symptom of cardiac failure.
- Non-allergic bronchospasm: Caution in patients with non-allergic bronchospasm or a history of it (for example chronic bronchitis or emphysema), since bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta-2 receptors may be blocked.
- Diminished pulmonary function: Caution in any patient with known diminished pulmonary function.
- Major surgery: Withdrawal of beta-blockers before major surgery is controversial; beta-blockade impairs the heart's response to reflex stimuli and may augment the risk of general anesthesia, and some patients have had protracted severe hypotension during anesthesia. Gradual withdrawal before elective surgery may be appropriate, and if necessary during surgery the effects may be reversed by sufficient doses of agonists such as isoproterenol, dopamine, dobutamine or levarterenol.
- Diabetes mellitus: May mask the signs and symptoms of acute hypoglycemia; caution in patients subject to spontaneous hypoglycemia and in diabetic patients, especially those with labile diabetes, who are receiving insulin or oral hypoglycemic agents.
- Thyrotoxicosis: May mask certain clinical signs of hyperthyroidism such as tachycardia; manage patients suspected of developing thyrotoxicosis carefully to avoid abrupt withdrawal, which might precipitate a thyroid storm.
- Hypersensitivity to other beta-blockers: Caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents.
- Angle-closure glaucoma: The immediate objective of treatment is to reopen the angle, which requires constricting the pupil with a miotic; carteolol has little or no effect on the pupil, so it should be used with a miotic and not alone.
- Risk from anaphylactic reaction: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.
- Muscle weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (for example diplopia, ptosis, and generalized weakness).
- Additive systemic beta-blockade: Use with caution in patients receiving a beta-adrenergic blocking agent orally, because of potential additive effects.
- Hypotension and marked bradycardia: Close observation is recommended with catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Common Side Effects
Transient eye irritation, burning, tearing, conjunctival hyperemia, and edema occurred in about 1 of 4 patients. Blurred and cloudy vision, photophobia, decreased night vision, ptosis, blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally. As is characteristic of nonselective adrenergic blocking agents, carteolol may cause bradycardia and decreased blood pressure. Cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, and taste perversion were occasionally reported. Other reactions reported with ophthalmic nonselective beta-blockers include arrhythmia, syncope, heart block, cerebral vascular accident, congestive heart failure, bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, and masked symptoms of hypoglycemia in insulin-dependent diabetics.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus. In animals, increased resorptions and decreased fetal weights occurred in rabbits and rats at maternally toxic doses approximately 1052 and 5264 times the maximum recommended human oral dose, and a dose-related increase in wavy ribs appeared in rat fetuses at approximately 212 times that dose.
Lactation: Excretion in human milk is unknown, although carteolol is excreted in breast milk in animal studies; exercise caution in nursing mothers.
Safety and effectiveness in pediatric patients have not been established.